New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
06:18 EDTRHHBYEMA warns that stolen Roche drug found on market
The European Medicines Agency has been informed that vials of the cancer medicine Herceptin, thought to have been stolen in Italy, including from hospitals, have been tampered with and re-introduced under false credentials into the supply chain in some countries. This is currently being investigated by Member State authorities and updates will be provided as more information becomes available. Italian law enforcement authorities are currently investigating the theft and are looking at whether other medicines may also be affected. No affected product has so far been identified at hospital level and there are no reports that any harm has come to patients in relation to the falsified medicine and authorities are working to avoid this. The marketing authorisation holder for Herceptin is Roche.
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
07:18 EDTRHHBYG Corp to hold annual meeting
Subscribe for More Information
06:14 EDTRHHBYPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
09:06 EDTRHHBYRoche receives orphan status for treatment of pemphigus vulgaris
The FDA granted Roche's Genentech unit orphan status for rituximab, its treatment of pemphigus vulgaris.
07:05 EDTRHHBYRoche and BioMed X enter collaboration agreement to develop sensor technology
Subscribe for More Information
February 23, 2015
06:21 EDTRHHBYFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
February 20, 2015
16:48 EDTRHHBYDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
07:23 EDTRHHBYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 19, 2015
18:25 EDTRHHBYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
09:09 EDTRHHBYLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
06:45 EDTRHHBYStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
05:31 EDTRHHBYExelixis announces acceptance of NDA for Genentech cobimetinib
Subscribe for More Information
05:26 EDTRHHBYFDA grants Genentech cobimetinib priority review for combination use
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use